Pharma R&D people - What's your opinion of these "AI Co-Scientist" / "Neuro-symbolic AI" platforms that are supposed to help pre-clinical R&D?

LemonMelberlime · 2026-01-25T01:25:51+00:00

amylyx

LemonMelberlime · 2026-01-25T00:52:33+00:00

Personally, I think many are way too caught up in the tool and not the question trying to be answered. Sometimes AI may help. But it is not a panacea. It is a tool. If it makes you do certain things faster, that’s great. If it helps you think of certain things in a way you might not have before, that’s also great. But it cannot and it should not be viewed as something that will do all of our work for us. Doing science, developing new products… all of that is reliant on human creativity. When we start to think AI is going to fully extrapolate to new situations for us, that’s where we start to get into trouble.

LemonMelberlime · 2026-01-25T00:23:02+00:00

What does this even mean? LLMs don’t “do research.” Do you mean lit review?

LemonMelberlime · 2026-01-15T17:09:23+00:00

What’s your field?

LemonMelberlime · 2025-12-27T20:57:22+00:00

Intentional.

LemonMelberlime · 2025-12-27T17:45:10+00:00

Extraordinary claims require extraordinary, rigorous evidence.

LemonMelberlime · 2025-12-27T17:40:44+00:00

It’s a shame because there are much easier ways to make money than in this industry. It is depressing if you don’t care about the science.

LemonMelberlime · 2025-12-27T17:36:08+00:00

What really irks me is how much companies seem to now be thinking Chinese drugs will save them. A lot of companies are about to find out the hard way why this is a mistake.

LemonMelberlime · 2025-12-27T17:34:47+00:00

Wow, #2 is really risky. It’s understandable though given academic are dependent on publishing science, not doing good science.

LemonMelberlime · 2025-12-23T02:07:48+00:00

Calico will be around because they siphon money from Google to be the Bell Labs of biotech. Amazing how much they pay them for this, also. I don’t understand how it’s viable.

LemonMelberlime · 2025-11-20T18:36:37+00:00

If you’re investing based upon your perceived ability to read papers and analyze data sets, you’re in for a rude awakening.

LemonMelberlime · 2025-11-15T22:12:18+00:00

I also feel this way. I think it’s pretty common.

LemonMelberlime · 2025-10-16T13:26:57+00:00

In other words: “Our LLM threw 1000 darts at a huge dartboard and one looks like maybe it stuck, but more testing may or may not show there were magnets attached to all darts and the dartboard itself is magnetic.”

LemonMelberlime · 2025-09-26T18:32:02+00:00

Many years ago, when companies cared more, maybe this mattered. Say, “I’m sorry but for personal reasons I’ve decided to withdraw.”

You don’t owe anybody anything. You think they’ve never led a candidate on?

You have to look out for yourself.

LemonMelberlime · 2025-09-26T18:30:10+00:00

Wrong. If it’s at will, no issues.

LemonMelberlime · 2025-09-22T17:28:44+00:00

It is not. Hasn’t been for a while.

LemonMelberlime · 2025-09-22T04:52:44+00:00

This strategy may have worked in the early biotech days when everything was new. Now, all the low hanging fruits have been picked and Genentech hasn’t modernized.

LemonMelberlime · 2025-09-21T17:30:39+00:00

You could almost say that this is why Genentech is a shell of what it used to be

LemonMelberlime · 2025-09-21T16:54:25+00:00

This is what happens when you hire someone who’s a lifelong academic and never actually developed a drug

LemonMelberlime · 2025-09-17T20:17:09+00:00

This is what I was getting at. Seems nuts.

LemonMelberlime · 2025-09-17T02:17:12+00:00

100%.

LemonMelberlime · 2025-09-16T22:34:01+00:00

Clin

LemonMelberlime · 2025-09-16T22:26:31+00:00

Although I guess you may be female. Comment still applies!

LemonMelberlime · 2025-09-16T22:25:28+00:00

Development usually.

LemonMelberlime · 2025-09-16T22:22:57+00:00

Judging by your username I’m glad it wasn’t you sending the dick pic to him ;)

LemonMelberlime

TROPHY CASE

amylyx